logo
Why is it becoming harder to lose weight? And should Ozempic step in where willpower fails?

Why is it becoming harder to lose weight? And should Ozempic step in where willpower fails?

The Hindua day ago
Find it hard to stop at exactly one potato chip or cookie? And why does a bar of chocolate fill you up in ways that fruit cannot, when you are craving a sweet treat on a stressful work day?
Going by Food Noise: How weight loss medications & smart nutrition can silence your cravings, a new book by Jack Mosley, which delves into the GLP-1 drug landscape, the reason is more sinister than you think. According to it, the big food industry, which took off around the same time as the Beatles, 'began processing food in clever ways to entice us to buy and eat more,' around then, which in turn led to an acceleration of both their bottom lines and the obesity epidemic.
These 'clever concoctions of salt, fat, sugar and carbs that you would not see in 'whole foods' or in nature' are especially hard to resist when they have 'this two-to-one, carbohydrate to fat ratio, which is the same ratio you see in breast milk,' says the Manchester-based 33-year-old, who studied medicine at Newcastle University and holds a Masters of Research in diabetes.
This particular ratio, not typically found in most whole foods, 'sends our primitive stone-age brains haywire,' he says, pointing out that while our genes have not changed dramatically over the last few millennia, our food environment has. 'We are adapted for the Savannah and the Stone Age lifestyle, not for our Western diets. Obesity is a clear sign that our hunter-gatherer bodies are struggling,' writes Dr. Mosley in the book.
Enter Ozempic
Obesity is a complex problem, not simply, as it is often assumed, a behavioural issue stemming from a lack of self-control, gluttony or sheer laziness. 'Willpower is somewhat overrated, and, if you look back at the last sixty years, we've not had a collective collapse of willpower,' he says. Instead, we live in a food environment in which we are surrounded by an abundance of ultraprocessed foods that are designed to be overeaten, leading to persistent food noise, 'your cravings…that voice that tells you to grab the extra slice of cake, crisps or chocolate bar,' says Dr. Mosley. 'So, it is very difficult in today's age to lose weight.'
This is where GLP-1 drugs, aka glucagon-like peptide-1 receptor agonists, a class of medications primarily used to treat type 2 diabetes, which are now also being used to manage obesity, can help. 'They work on three areas,' he says, listing them out. Firstly, he says, they reduce blood sugar levels, which is why they've been used to treat diabetes for nearly 20 years. They also act on the gut, slowing down your digestive tract and keeping you full longer. 'Thirdly, and this is where they're so interesting and have a big impact on weight loss, they act on the brain, reducing appetite,' he says.
Since these drugs, which include Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound, seem to regulate the brain's reward centres and regulate cravings, 'they are so effective at silencing that food noise. That is one of the reasons why people lose a lot of weight,' says Dr. Mosley, who thinks of them as a tool in the toolbox to combat obesity, and not a replacement for other traditional weight-management strategies, such as a healthy diet, hydration, adequate sleep, stress management and exercise.
Genesis
The idea for Food Noise emerged from a conversation between Dr. Mosley and his mother, Clare Bailey Mosley, while they were travelling on a busy train from Austria to Germany. While not a magic fix, 'these are really powerful drugs', and he also could see how valuable they could be for certain people, he says. He has been closely following GLP-1s and was struck by the lack of information available about them. 'I felt that people should be well-informed about them. So, I kind of said, 'why don't I write a book about it?'
'It is the Wild West out there. I don't think people are provided that much information about how they work, their risks and rewards, their side effects and how to manage them,' he says.
Also, because they are expensive and there is such a massive demand for them, 'there are a lot of sharks and cowboys out there who are providing fake GLP-1s as well,' he says. Another concern he has is that, since they're so accessible, they may be misused by people who don't need them: those who are metabolically well with a healthy BMI, trying to drop a few vanity pounds or people with eating disorders for whom 'they could be really, really dangerous.'
The Mosley mission
Son of the late writer, television presenter and health maverick, Michael Mosley, best known for his frequent forays into self-experimentation and popularising the 5:2 diet, Dr. Jack Mosley admits that his father significantly influenced his interest in metabolic health and weight management. Michael Mosley, who would do all these 'weird whacky things… in the name of science', including ingesting tapeworms, keeping a pet leech and even undergoing a colonoscopy on camera, had also been deeply interested in these new weight loss drugs, he says.
'My dad and I talked about these GLP1s quite substantially. They were clearly going to make a massive impact on the diet and weight loss world, but we also discussed the risks that were emerging,' says Dr. Mosley, adding that carrying his father's legacy forward, 'whether it was helping people reverse Type 2 diabetes, lose weight or even making one or two small changes in their habits', was important to him. 'I wanted to continue this Mosley mission. That has been really important to me in the aftermath of his death.'
In addition to offering a nuanced take on these drugs, neither proclaiming them to be a magic bullet nor deriding them as an easy shortcut to weight loss, Food Noise also contains a selection of recipes created by Dr. Mosley's mother, Clare, which appear to be primarily influenced by the Mediterranean diet, 'the most evidence-based dietary pattern in the world,' he says of the diet, which is packed with plenty of vegetables, fruits, nuts, seeds, legumes, some oily fish and plenty of olive oil. 'It is a dietary pattern in that it is good for your health and easier to stick to,' he says.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose

Economic Times

time14 minutes ago

  • Economic Times

Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose

Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of Wall Street's expectations. Despite the positive results, shares of Eli Lilly fell, while rival Novo Nordisk's shares rose. The company plans to seek regulatory approval for the pill by the end of 2025. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Eli Lily on daily GLP-1 pills Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults."With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need."Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy . In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound.'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.'Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.

Acko ramps up health insurance play to expand healthcare reach
Acko ramps up health insurance play to expand healthcare reach

Mint

time38 minutes ago

  • Mint

Acko ramps up health insurance play to expand healthcare reach

BENGALURU : Nearly a year after acquiring Better Capital-backed chronic-care startup OneCare, insurtech Acko Technology and Services Pvt. Ltd is doubling down on health insurance offerings, expanding partnerships with hospitals and clinics to tap into the growing opportunity in the space, a top executive told Mint. The Bengaluru-based unicorn acquired the digital chronic-care management company in an all-cash deal in 2024 to enter the health insurance segment. The firm, which began with auto insurance in 2016, is now working on integrating the entire process of buying health insurance—from picking a lab for medical testing to interacting with a hospital for claims. 'The problem in the health insurance industry today is that the burden of the entire process is on the customer. If there's a breakdown in the system, they're on their own. We're working towards integrating the entire system on our app and actually hand-holding customers to pick the best testing labs and hospitals," Animesh Das, managing director and chief executive of Acko General Insurance, told Mint in an interview. Acko aims to capitalize on the booming Indian healthcare sector, which is valued at over $372 billion and is growing at a compound annual growth rate of 21% since 2014, according to estimates by government think tank Niti Aayog. With health premiums already accounting for more than half of Acko's overall premium income, the firm has invested substantially to grow the segment over the last year, Das said. Acko has secured nearly $450 million in funding from investors, including Multiples PE, Accel, Elevation Capital, and General Atlantic. It was last valued at $1.1 billion in October 2021. Last week, cricketer M.S. Dhoni announced his investment in the firm and hopped on board as its brand ambassador. In the healthcare sector, Acko is in direct competition with players such as PharmEasy, HealthQuad-backed HealthifyMe, and HealthPlix that provide healthcare services such as diagnostic tests and doctor consultations. Motor insurance slowdown While Acko is yet to officially file its 2024-25 financials with the Registrar of Companies (RoC), it witnessed 'measured growth" during the year. 'It was a year of learning to know what levers will drive growth for us. Doubling down on health is a product of that learning," Das said. 'Healthcare services are a long-term game for us." The integration of its various insurance services will also result in customers engaging with the platform more regularly, which otherwise tends to be an annual activity. In the fiscal year ended March 2024, Acko's revenue climbed to ₹2,106 crore from ₹1,758 crore in the year prior, filings available with the RoC showed. Its losses narrowed marginally to ₹670 crore from ₹738 crore. Acko is among venture capital firm Elevation Capital's portfolio companies looking to get publicly listed soon. Mint reported on 6 August that the VC firm plans to take at least nine portfolio companies public over the next 12-24 months, as it gears up to monetize its portfolio amid improving public market conditions for tech and consumer startups in the country. Das declined to comment on the IPO timeline. Acko is evolving its model to keep up with a slowdown in the industry. The firm has struck a partnership with American carmaker Tesla Inc. as the insurance partner in India. 'Tesla's branding of a new-age automaker designed for young and aspirational buyers ties in well with the shift in consumer cohorts in our insurance products," Das said. A July Nuvama report said the insurance industry in India is slowing primarily due to moderation in auto sales and a drop in corporate renewal policies. Motor insurance growth has slowed down due to weak retail motor sales. The gross direct premium income (GDPI) in the motor segment rose 6.7% in June 2025, compared to 8.2% in the year-ago period.

Calicut varsity ties up with coop. tech company to develop supercapacitors
Calicut varsity ties up with coop. tech company to develop supercapacitors

The Hindu

time44 minutes ago

  • The Hindu

Calicut varsity ties up with coop. tech company to develop supercapacitors

The Advanced Materials Research Lab at the University of Calicut has partnered with a Parappanangadi-based tech company to develop supercapacitors, the high-capacity energy storage devices, using indigenous methods. University sources said on Thursday that the collaboration with Malabar Co-op Tech was aimed at taking a breakthrough material developed entirely in India from the lab to real-world applications. The research team lead by Yahya Ismail, Professor, Department of Chemistry, and his student, Sivakrishna Prakash, had been working for the past five years on developing a new-generation energy storage material that would address some of the biggest limitations in current supercapacitors. Ideal for electric vehicles The material combines polyaniline, a highly conductive polymer, with heteroatom-doped reduced graphene oxide, a modified carbon-based nanomaterial known for its exceptional surface area and electrical conductivity. Mr. Ismail and Mr. Prakash said that what sets this invention apart was the strong chemical bondingbetween the components, which would ensure high energy storage, rapid charging, and long-term durability. 'It can store more energy than typical supercapacitors, charge very quickly, and maintain performance for thousands of cycles—making it ideal for electric vehicles, solar energy systems, and portable electronics,' they said. M.K. Jaison, project head, Malabar Co-op Tech, said that the company would provide the engineering support, infrastructure, and technology platform required to manufacture complete supercapacitor devices, facilitating a seamless transition from lab-scale innovation to real-world application. He said that this was for the first time that a cooperative sector body was getting directly engaged in the high-tech energy storage manufacturing domain. Mr. Jaison said that India currently depends on imported electrode materials, primarily from China, to assemble supercapacitors. This over-reliance on imports and limited domestic research and development have historically stifled indigenous innovation and self-reliance in this critical clean energy segment. By focussing on both material development and device manufacturing within India, the project represents a key step towards building a fully localised supply chain for advanced energy storage solutions. It is expected to open up possibilities for large-scale commercialisation, technology export, and job creation in the clean energy sector, he added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store